Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 12/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156219 | 0.94 | PREP (0.54) | PREPPSMB5FAPF2 | |
| SCHEMBL24025130 | 0.94 | PREP (0.54) | PREPPSMB5FAPF2 | |
| SCHEMBL8234287 | 0.91 | PREP (0.56) | PREPPSMB5FAPF2 | |
| SCHEMBL14161094 | 0.91 | PREP (0.54) | PREPPSMB5FAP | |
| SCHEMBL14161093 | 0.91 | PREP (0.54) | PREPPSMB5FAP | |
| SCHEMBL12658549 | 0.88 | PREP (0.53) | PREPPSMB5FAPF2 | |
| SCHEMBL21156692 | 0.86 | PREP (0.51) | PREPPSMB5FAPF2 | |
| SCHEMBL26853210 | 0.86 | PREP (0.51) | PREPPSMB5FAPF2 | |
| SCHEMBL25892010 | 0.85 | PREP (0.51) | PREPPSMB5F2 | |
| SCHEMBL21747116 | 0.84 | PSMB5 (0.37) | PREPPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-9839646-B2 | Small molecule enhancer for dendritic cell cancer vaccines | TRUSTEES OF TUFTS COLLEGE (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839646-B2 | Small molecule enhancer for dendritic cell cancer vaccines | TRUSTEES OF TUFTS COLLEGE (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160310513-A1 | SMALL MOLECULE ENHANCER FOR DENDRITIC CELL CANCER VACCINES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-27 | — | — | US | disclosed |
| US-20160310513-A1 | SMALL MOLECULE ENHANCER FOR DENDRITIC CELL CANCER VACCINES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-27 | — | — | US | disclosed |
| US-9284337-B2 | Small molecule enhancer for dendritic cell cancer vaccines | TRUSTEES OF TUFTS COLLEGE (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140271725-A1 | Small Molecule Enhancer for Dendritic Cell Cancer Vaccines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310513-A1 | SMALL MOLECULE ENHANCER FOR DENDRITIC CELL CANCER VACCINES | DPEP1, ADAM17, TMPRSS15 | PREP 102/4885PSMB5 1973/4885FAP 629/4885 |
| US-20140271725-A1 | Small Molecule Enhancer for Dendritic Cell Cancer Vaccines | DPP7, DPP3, DPP4 | PREP 61/4885PSMB5 2004/4885FAP 121/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PREP 445/4885PSMB5 2283/4885FAP 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.